Relevant NewsDaily Edition
The FDA has approved Moderna's mFLUSIVA, an mRNA-based flu vaccine, for adults aged 50 and older. The approval marks a significant expansion of mRNA technology beyond COVID-19 into seasonal influenza vaccination, representing Moderna's first major flu shot authorization.
Why it matters: This approval validates mRNA platform versatility for routine vaccines and opens a substantial new market opportunity as major pharma races to develop next-generation seasonal immunizations.
